Skip to main content
Top
Published in: BMC Infectious Diseases 1/2020

01-12-2020 | Campylobacter | Research article

Validation of the T86I mutation in the gyrA gene as a highly reliable real time PCR target to detect Fluoroquinolone-resistant Campylobacter jejuni

Authors: Nereyda Espinoza, Jesús Rojas, Simon Pollett, Rina Meza, Lilian Patiño, Manuel Leiva, Máximo Camiña, Manuela Bernal, Nathanael D. Reynolds, Ryan Maves, Drake H. Tilley, Matthew Kasper, Mark P. Simons

Published in: BMC Infectious Diseases | Issue 1/2020

Login to get access

Abstract

Background

Campylobacter jejuni is a leading cause of bacterial diarrhea worldwide, and increasing rates of fluoroquinolone (FQ) resistance in C. jejuni are a major public health concern. The rapid detection and tracking of FQ resistance are critical needs in developing countries, as these antimicrobials are widely used against C. jejuni infections. Detection of point mutations at T86I in the gyrA gene by real-time polymerase chain reaction (RT-PCR) is a rapid detection tool that may improve FQ resistance tracking.

Methods

C. jejuni isolates obtained from children with diarrhea in Peru were tested by RT-PCR to detect point mutations at T86I in gyrA. Further confirmation was performed by sequencing of the gyrA gene.

Results

We detected point mutations at T86I in the gyrA gene in 100% (141/141) of C. jejuni clinical isolates that were previously confirmed as ciprofloxacin-resistant by E-test. No mutations were detected at T86I in gyrA in any ciprofloxacin-sensitive isolates.

Conclusions

Detection of T86I mutations in C. jejuni is a rapid, sensitive, and specific method to identify fluoroquinolone resistance in Peru. This detection approach could be broadly employed in epidemiologic surveillance, therefore reducing time and cost in regions with limited resources.
Literature
1.
go back to reference Nachamkin I, Szymanski CM, Blaser MJ. Campylobacter. 3rd ed. Washington, DC: ASM Press; 2008. xv. p. 716.CrossRef Nachamkin I, Szymanski CM, Blaser MJ. Campylobacter. 3rd ed. Washington, DC: ASM Press; 2008. xv. p. 716.CrossRef
2.
go back to reference Allos BM. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis. 2001;32(8):1201–6.CrossRef Allos BM. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis. 2001;32(8):1201–6.CrossRef
3.
go back to reference Kirkpatrick BD, Tribble DR. Update on human campylobacter jejuni infections. Curr Opin Gastroenterol. 2011;27(1):1–7.CrossRef Kirkpatrick BD, Tribble DR. Update on human campylobacter jejuni infections. Curr Opin Gastroenterol. 2011;27(1):1–7.CrossRef
4.
go back to reference Lee G, Paredes Olortegui M, Peñataro Yori P, Black RE, Caulfield L, Banda Chavez C, et al. Effects of Shigella-, campylobacter- and ETEC-associated diarrhea on childhood growth. Pediatr Infect Dis J. 2014;33(10):1004–9.CrossRef Lee G, Paredes Olortegui M, Peñataro Yori P, Black RE, Caulfield L, Banda Chavez C, et al. Effects of Shigella-, campylobacter- and ETEC-associated diarrhea on childhood growth. Pediatr Infect Dis J. 2014;33(10):1004–9.CrossRef
5.
go back to reference Francois R, Yori PP, Rouhani S, Salas MS, Olortegui MP, Trigoso DR, Pisanic N, Burga R, Meza R, et al. The other Campylobacter: Not innocent bystanders in endemic diarrhea and dysentery in children in low-income settings. PLOS Neglected Tropical Dis. 2018;12(2):e0006200. Francois R, Yori PP, Rouhani S, Salas MS, Olortegui MP, Trigoso DR, Pisanic N, Burga R, Meza R, et al. The other Campylobacter: Not innocent bystanders in endemic diarrhea and dysentery in children in low-income settings. PLOS Neglected Tropical Dis. 2018;12(2):e0006200.
6.
go back to reference Lee G, Pan PW, Pablo P, Maribel P, Drake T, Michael G, Richard O, Rosa B, Cesar B, Margaret K. Symptomatic and Asymptomatic Campylobacter Infections Associated with Reduced Growth in Peruvian Children. PLOS Neglected Tropical Dis. 2013;7(1):e2036. Lee G, Pan PW, Pablo P, Maribel P, Drake T, Michael G, Richard O, Rosa B, Cesar B, Margaret K. Symptomatic and Asymptomatic Campylobacter Infections Associated with Reduced Growth in Peruvian Children. PLOS Neglected Tropical Dis. 2013;7(1):e2036.
7.
go back to reference Alfredson DA, Korolik V. Antibiotic resistance and resistance mechanisms in campylobacter jejuni and campylobacter coli. FEMS Microbiol Lett. 2007;277(2):123–32.CrossRef Alfredson DA, Korolik V. Antibiotic resistance and resistance mechanisms in campylobacter jejuni and campylobacter coli. FEMS Microbiol Lett. 2007;277(2):123–32.CrossRef
8.
go back to reference Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P, Nachamkin I. Quinolone and macrolide resistance in campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis. 2001;7(1):24–34.CrossRef Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P, Nachamkin I. Quinolone and macrolide resistance in campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis. 2001;7(1):24–34.CrossRef
9.
go back to reference Niwa H, Chuma T, Okamoto K, Itoh K. Simultaneous detection of mutations associated with resistance to macrolides and quinolones in campylobacter jejuni and C. coli using a PCR-line probe assay. Int J Antimicrob Agents. 2003;22(4):374–9.CrossRef Niwa H, Chuma T, Okamoto K, Itoh K. Simultaneous detection of mutations associated with resistance to macrolides and quinolones in campylobacter jejuni and C. coli using a PCR-line probe assay. Int J Antimicrob Agents. 2003;22(4):374–9.CrossRef
10.
go back to reference Fabrega A, Sanchez-Cespedes J, Soto S, Vila J. Quinolone resistance in the food chain. Int J Antimicrob Agents. 2008;31(4):307–15.CrossRef Fabrega A, Sanchez-Cespedes J, Soto S, Vila J. Quinolone resistance in the food chain. Int J Antimicrob Agents. 2008;31(4):307–15.CrossRef
11.
go back to reference Taylor DN, Sanchez JL, Candler W, Thornton S, McQueen C, Echeverria P. Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial. Ann Intern Med. 1991;114(9):731–4.CrossRef Taylor DN, Sanchez JL, Candler W, Thornton S, McQueen C, Echeverria P. Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial. Ann Intern Med. 1991;114(9):731–4.CrossRef
12.
go back to reference Holloway K, Mathai E, Gray A. Surveillance of antimicrobial resistance in resource-constrained settings - experience from five pilot projects. Tropical Med Int Health. 2011;16(3):368–74.CrossRef Holloway K, Mathai E, Gray A. Surveillance of antimicrobial resistance in resource-constrained settings - experience from five pilot projects. Tropical Med Int Health. 2011;16(3):368–74.CrossRef
13.
go back to reference Holloway K, Mathai E, Gray A. Surveillance of community antimicrobial use in resource-constrained settings--experience from five pilot projects. Tropical Med Int Health. 2011;16(2):152–61.CrossRef Holloway K, Mathai E, Gray A. Surveillance of community antimicrobial use in resource-constrained settings--experience from five pilot projects. Tropical Med Int Health. 2011;16(2):152–61.CrossRef
14.
go back to reference Kotwani A, Holloway K. Trends in antibiotic use among outpatients in New Delhi, India. BMC Infect Dis. 2011;11:99.CrossRef Kotwani A, Holloway K. Trends in antibiotic use among outpatients in New Delhi, India. BMC Infect Dis. 2011;11:99.CrossRef
15.
go back to reference Said MM, El-Mohamady H, El-Beih FM, Rockabrand DM, Ismail TF, Monteville MR, et al. Detection of gyrA mutation among clinical isolates of campylobacter jejuni isolated in Egypt by MAMA-PCR. J Infect Dev Ctries. 2010;4(9):546–54.CrossRef Said MM, El-Mohamady H, El-Beih FM, Rockabrand DM, Ismail TF, Monteville MR, et al. Detection of gyrA mutation among clinical isolates of campylobacter jejuni isolated in Egypt by MAMA-PCR. J Infect Dev Ctries. 2010;4(9):546–54.CrossRef
16.
go back to reference Dionisi AM, Luzzi I, Carattoli A. Identification of ciprofloxacin-resistant campylobacter jejuni and analysis of the gyrA gene by the LightCycler mutation assay. Mol Cell Probes. 2004;18(4):255–61.CrossRef Dionisi AM, Luzzi I, Carattoli A. Identification of ciprofloxacin-resistant campylobacter jejuni and analysis of the gyrA gene by the LightCycler mutation assay. Mol Cell Probes. 2004;18(4):255–61.CrossRef
17.
go back to reference Bakeli G, Sato K, Kumita W, Saito R, Ono E, Chida T, et al. Antimicrobial susceptibility and mechanism of quinolone resistance in campylobacter jejuni strains isolated from diarrheal patients in a hospital in Tokyo. J Infect Chemother. 2008;14(5):342–8.CrossRef Bakeli G, Sato K, Kumita W, Saito R, Ono E, Chida T, et al. Antimicrobial susceptibility and mechanism of quinolone resistance in campylobacter jejuni strains isolated from diarrheal patients in a hospital in Tokyo. J Infect Chemother. 2008;14(5):342–8.CrossRef
18.
go back to reference Kinana AD, Cardinale E, Bahsoun I, Tall F, Sire JM, Garin B, et al. Analysis of topoisomerase mutations in fluoroquinolone-resistant and -susceptible campylobacter jejuni strains isolated in Senegal. Int J Antimicrob Agents. 2007;29(4):397–401.CrossRef Kinana AD, Cardinale E, Bahsoun I, Tall F, Sire JM, Garin B, et al. Analysis of topoisomerase mutations in fluoroquinolone-resistant and -susceptible campylobacter jejuni strains isolated in Senegal. Int J Antimicrob Agents. 2007;29(4):397–401.CrossRef
19.
go back to reference Oporto B, Juste RA, Hurtado A. Phenotypic and genotypic antimicrobial resistance profiles of campylobacter jejuni isolated from cattle, sheep, and free-range poultry Faeces. Int J Microbiol. 2009;2009:456573.CrossRef Oporto B, Juste RA, Hurtado A. Phenotypic and genotypic antimicrobial resistance profiles of campylobacter jejuni isolated from cattle, sheep, and free-range poultry Faeces. Int J Microbiol. 2009;2009:456573.CrossRef
20.
go back to reference Han J, Wang Y, Sahin O, Shen Z, Guo B, Shen J, et al. A fluoroquinolone resistance associated mutation in gyrA affects DNA supercoiling in campylobacter jejuni. Front Cell Infect Microbiol. 2012;2:21.CrossRef Han J, Wang Y, Sahin O, Shen Z, Guo B, Shen J, et al. A fluoroquinolone resistance associated mutation in gyrA affects DNA supercoiling in campylobacter jejuni. Front Cell Infect Microbiol. 2012;2:21.CrossRef
21.
go back to reference Zirnstein G, Li Y, Swaminathan B, Angulo F. Ciprofloxacin resistance in campylobacter jejuni isolates: detection of gyrA resistance mutations by mismatch amplification mutation assay PCR and DNA sequence analysis. J Clin Microbiol. 1999;37(10):3276–80.CrossRef Zirnstein G, Li Y, Swaminathan B, Angulo F. Ciprofloxacin resistance in campylobacter jejuni isolates: detection of gyrA resistance mutations by mismatch amplification mutation assay PCR and DNA sequence analysis. J Clin Microbiol. 1999;37(10):3276–80.CrossRef
22.
go back to reference Wang Y, Huang WM, Taylor DE. Cloning and nucleotide sequence of the campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations. Antimicrob Agents Chemother. 1993;37(3):457–63.CrossRef Wang Y, Huang WM, Taylor DE. Cloning and nucleotide sequence of the campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations. Antimicrob Agents Chemother. 1993;37(3):457–63.CrossRef
23.
go back to reference Beckmann L, Muller M, Luber P, Schrader C, Bartelt E, Klein G. Analysis of gyrA mutations in quinolone-resistant and -susceptible campylobacter jejuni isolates from retail poultry and human clinical isolates by non-radioactive single-strand conformation polymorphism analysis and DNA sequencing. J Appl Microbiol. 2004;96(5):1040–7.CrossRef Beckmann L, Muller M, Luber P, Schrader C, Bartelt E, Klein G. Analysis of gyrA mutations in quinolone-resistant and -susceptible campylobacter jejuni isolates from retail poultry and human clinical isolates by non-radioactive single-strand conformation polymorphism analysis and DNA sequencing. J Appl Microbiol. 2004;96(5):1040–7.CrossRef
24.
go back to reference Chatzipanagiotou S, Papavasileiou E, Lakumenta A, Makri A, Nicolaou C, Chantzis K, et al. Antimicrobial susceptibility patterns of campylobacter jejuni strains isolated from hospitalized children in Athens, Greece. J Antimicrob Chemother. 2002;49(5):803–5.CrossRef Chatzipanagiotou S, Papavasileiou E, Lakumenta A, Makri A, Nicolaou C, Chantzis K, et al. Antimicrobial susceptibility patterns of campylobacter jejuni strains isolated from hospitalized children in Athens, Greece. J Antimicrob Chemother. 2002;49(5):803–5.CrossRef
25.
go back to reference Sonnevend A, Rotimi VO, Kolodziejek J, Usmani A, Nowotny N, Pal T. High level of ciprofloxacin resistance and its molecular background among campylobacter jejuni strains isolated in the United Arab Emirates. J Med Microbiol. 2006;55(Pt 11):1533–8.CrossRef Sonnevend A, Rotimi VO, Kolodziejek J, Usmani A, Nowotny N, Pal T. High level of ciprofloxacin resistance and its molecular background among campylobacter jejuni strains isolated in the United Arab Emirates. J Med Microbiol. 2006;55(Pt 11):1533–8.CrossRef
26.
go back to reference Oberhelman RA, Gilman RH, Sheen P, Cordova J, Zimic M, Cabrera L, et al. An intervention-control study of corralling of free-ranging chickens to control campylobacter infections among children in a Peruvian periurban shantytown. Am J Trop Med Hyg. 2006;74(6):1054–9.CrossRef Oberhelman RA, Gilman RH, Sheen P, Cordova J, Zimic M, Cabrera L, et al. An intervention-control study of corralling of free-ranging chickens to control campylobacter infections among children in a Peruvian periurban shantytown. Am J Trop Med Hyg. 2006;74(6):1054–9.CrossRef
27.
go back to reference Pollett S, Rocha C, Zerpa R, Patino L, Valencia A, Camina M, et al. Campylobacter antimicrobial resistance in Peru: a ten-year observational study. BMC Infect Dis. 2012;12:193.CrossRef Pollett S, Rocha C, Zerpa R, Patino L, Valencia A, Camina M, et al. Campylobacter antimicrobial resistance in Peru: a ten-year observational study. BMC Infect Dis. 2012;12:193.CrossRef
28.
go back to reference Luque A, Riveros M, Prada A, Ochoa T, Ruiz J. Virulence and Antimicrobial Reistance in Campylobacter spp. from a Peruvian Pediatric Cohort. Hindawi Scientifica. 2017;2017:7848926. Luque A, Riveros M, Prada A, Ochoa T, Ruiz J. Virulence and Antimicrobial Reistance in Campylobacter spp. from a Peruvian Pediatric Cohort. Hindawi Scientifica. 2017;2017:7848926.
29.
go back to reference Vandamme P, Van Doorn LJ, al Rashid ST, Quint WG, van der Plas J, Chan VL, et al. Campylobacter hyoilei Alderton et al. 1995 and campylobacter coli Veron and Chatelain 1973 are subjective synonyms. Int J Syst Bacteriol. 1997;47(4):1055–60.CrossRef Vandamme P, Van Doorn LJ, al Rashid ST, Quint WG, van der Plas J, Chan VL, et al. Campylobacter hyoilei Alderton et al. 1995 and campylobacter coli Veron and Chatelain 1973 are subjective synonyms. Int J Syst Bacteriol. 1997;47(4):1055–60.CrossRef
30.
go back to reference Baker CN. The E-test and campylobacter jejuni. Diagn Microbiol Infect Dis. 1992;15(5):469–72.CrossRef Baker CN. The E-test and campylobacter jejuni. Diagn Microbiol Infect Dis. 1992;15(5):469–72.CrossRef
31.
go back to reference CLSI Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria`; Approved Guidelines - 2nd Edition. CLSI document M45-A2. Wayne, PA. 2016. CLSI Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria`; Approved Guidelines - 2nd Edition. CLSI document M45-A2. Wayne, PA. 2016.
33.
go back to reference Newcombe RG. Two-Sided Confidence Intervals for the Single Proportion: Comparison of Seven Methods. Statistics Med. 1998;17:857–72.CrossRef Newcombe RG. Two-Sided Confidence Intervals for the Single Proportion: Comparison of Seven Methods. Statistics Med. 1998;17:857–72.CrossRef
34.
go back to reference Ge B, White DG, McDermott PF, Girard W, Zhao S, Hubert S, et al. Antimicrobial-resistant campylobacter species from retail raw meats. Appl Environ Microbiol. 2003;69(5):3005–7.CrossRef Ge B, White DG, McDermott PF, Girard W, Zhao S, Hubert S, et al. Antimicrobial-resistant campylobacter species from retail raw meats. Appl Environ Microbiol. 2003;69(5):3005–7.CrossRef
35.
go back to reference Fernandez H. Campylobacter and campylobacteriosis: a view from South America. Rev Peru Med Exp Salud Publica. 2011;28(1):121–7.CrossRef Fernandez H. Campylobacter and campylobacteriosis: a view from South America. Rev Peru Med Exp Salud Publica. 2011;28(1):121–7.CrossRef
36.
go back to reference Luber P, Bartelt E, Genschow E, Wagner J, Hahn H. Comparison of Broth microdilution, E Test, and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni and Campylobacter coli. J Clin. Microbiol. 2003;41(3):1062–8. Luber P, Bartelt E, Genschow E, Wagner J, Hahn H. Comparison of Broth microdilution, E Test, and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni and Campylobacter coli. J Clin. Microbiol. 2003;41(3):1062–8.
Metadata
Title
Validation of the T86I mutation in the gyrA gene as a highly reliable real time PCR target to detect Fluoroquinolone-resistant Campylobacter jejuni
Authors
Nereyda Espinoza
Jesús Rojas
Simon Pollett
Rina Meza
Lilian Patiño
Manuel Leiva
Máximo Camiña
Manuela Bernal
Nathanael D. Reynolds
Ryan Maves
Drake H. Tilley
Matthew Kasper
Mark P. Simons
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2020
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-020-05202-4

Other articles of this Issue 1/2020

BMC Infectious Diseases 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.